摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[4-(3-nitro-phenoxy)-butyl]saccharin | 1004305-79-6

中文名称
——
中文别名
——
英文名称
N-[4-(3-nitro-phenoxy)-butyl]saccharin
英文别名
2-[4-(3-nitrophenoxy)butyl]-1,1-dioxo-1,2-benzothiazol-3-one
N-[4-(3-nitro-phenoxy)-butyl]saccharin化学式
CAS
1004305-79-6
化学式
C17H16N2O6S
mdl
——
分子量
376.39
InChiKey
WRIQKDRZKLEWAY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    26
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    118
  • 氢给体数:
    0
  • 氢受体数:
    6

反应信息

  • 作为产物:
    描述:
    参考文献:
    名称:
    Methods and Compounds for Modulating Cannabinoid Activity
    摘要:
    本文披露了一些抑制单酰基甘油脂肪酶(MGL)和脂肪酸酰胺水解酶(FAAH)作用的化合物和组合物,抑制MGL和FAAH的方法,调节大麻素受体的方法,以及治疗与大麻素受体调节相关的各种疾病的方法。
    公开号:
    US20110071178A1
点击查看最新优质反应信息

文献信息

  • FATTY ACID AMIDE HYDROLASE INHIBITORS
    申请人:Makriyannis Alexandros
    公开号:US20090306016A1
    公开(公告)日:2009-12-10
    Disclosed are compounds of formula R—X—Y that may be used to inhibit the action of fatty acid amide hydrolase (FAAH). Inhibition of fatty acid amide hydrolase (FAAH) will slow the normal degradation and inactivation of endogenous cannabinoid ligands by FAAH hydrolysis and allow higher levels of those endogenous cannabinergic ligands to remain present. These higher levels of endocannabinoid ligands provide increased stimulation of the cannabinoid CB1i and CB2 receptors and produce physiological effects related to the activation of the cannabinoid receptors. They will also enhance the effects of other exogenous cannabinergic ligands and allow them to produce their effects at lower concentrations as compared to systems in which fatty acid amide hydrolase (FAAH) action is hot inhibited. Thus, a compound that inhibits the inactivation of endogenous cannabinoid ligands by fatty acid amide hydrolase (FAAH) may increase the levels of endocannabinoids and, thus, enhance the activation of cannabinoid receptors. Thus, the compound may not directly modulate the cannabinoid receptors but has the effect of indirectly stimulating the cannabinoid receptors by increasing the levels of endocannabinoid ligands. It may also enhance the effects and duration of action of other exogenous cannabinergic ligands that are administered in order to elicit a cannabinergic response.
    公开了一种R-X-Y式化合物,可用于抑制脂肪酸酰胺解酶(FAAH)的作用。抑制脂肪酸酰胺解酶(FAAH)将减缓FAAH解作用引起的内源性大麻素配体的正常降解和失活,并允许更高平的内源性大麻素配体保持存在。这些更高平的内源性大麻素配体提供了对大麻素CB1i和CB2受体的增加刺激,并产生与大麻素受体激活相关的生理效应。它们还将增强其他外源性大麻素配体的效果,并允许它们在较低浓度下产生其效果,与不抑制脂肪酸酰胺解酶(FAAH)作用的系统相比。因此,一种抑制脂肪酸酰胺解酶(FAAH)对内源性大麻素配体失活的化合物可能会增加内源性大麻素平,从而增强大麻素受体的激活。因此,该化合物可能不直接调节大麻素受体,但通过增加内源性大麻素配体平间接刺激大麻素受体。它还可以增强其他外源性大麻素配体的效果和作用持续时间,这些配体被用于引发大麻素反应。
  • Fatty acid amide hydrolase inhibitors
    申请人:Makriyannis Alexandros
    公开号:US09102622B2
    公开(公告)日:2015-08-11
    Disclosed are compounds of formula R—X—Y that may be used to inhibit the action of fatty acid amide hydrolase (FAAH). Inhibition of fatty acid amide hydrolase (FAAH) will slow the normal degradation and inactivation of endogenous cannabinoid ligands by FAAH hydrolysis and allow higher levels of those endogenous cannabinergic ligands to remain present. These higher levels of endocannabinoid ligands provide increased stimulation of the cannabinoid CB1 and CB2 receptors and produce physiological effects related to the activation of the cannabinoid receptors. They will also enhance the effects of other exogenous cannabinergic ligands and allow them to produce their effects at lower concentrations as compared to systems in which fatty acid amide hydrolase (FAAH) action is hot inhibited. Thus, a compound that inhibits the inactivation of endogenous cannabinoid ligands by fatty acid amide hydrolase (FAAH) may increase the levels of endocannabinoids and, thus, enhance the activation of cannabinoid receptors. Thus, the compound may not directly modulate the cannabinoid receptors but has the effect of indirectly stimulating the cannabinoid receptors by increasing the levels of endocannabinoid ligands. It may also enhance the effects and duration of action of other exogenous cannabinergic ligands that are administered in order to elicit a cannabinergic response.
    本发明揭示了化合物R-X-Y的公式,可用于抑制脂肪酸酰胺解酶(FAAH)的作用。抑制脂肪酸酰胺解酶(FAAH)将减缓FAAH解对内源性大麻素配体的正常降解和失活,并允许更高平的内源性大麻素配体保持存在。这些更高平的内源性大麻素配体提供了对大麻素CB1和CB2受体的增强刺激,并产生与大麻素受体激活相关的生理效应。它们还增强了其他外源性大麻素配体的效果,并允许它们在相对于不抑制FAAH作用的系统中以较低的浓度产生其效果。因此,抑制脂肪酸酰胺解酶(FAAH)对内源性大麻素配体的失活的化合物可能增加内源性大麻素平,从而增强大麻素受体的激活。因此,该化合物可能不直接调节大麻素受体,但通过增加内源性大麻素配体平间接刺激大麻素受体。它还可以增强其他外源性大麻素配体的作用和持续时间,以引发大麻素反应。
  • MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY
    申请人:Makriyannis Alexandros
    公开号:US20110039874A1
    公开(公告)日:2011-02-17
    Disclosed are compounds and compositions that inhibit the action of monoacylglycerol lipase (MGL) and fatty acid amide hydrolase (FAAH), methods of inhibiting MGL and FAAH, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors.
    公开了一种抑制单酰基甘油脂肪酶(MGL)和脂肪酸酰胺解酶(FAAH)作用的化合物和组合物,抑制MGL和FAAH的方法,调节大麻素受体的方法,以及治疗与大麻素受体调节相关的各种疾病的方法。
  • US9102622B2
    申请人:——
    公开号:US9102622B2
    公开(公告)日:2015-08-11
  • [EN] FATTY ACID AMIDE HYDROLASE INHIBITORS<br/>[FR] INHIBITEURS D'AMIDE D'ACIDE GRAS HYDROLASE
    申请人:UNIV CONNECTICUT
    公开号:WO2008013963A2
    公开(公告)日:2008-01-31
    [EN] Disclosed are compounds of formula R-X-Y that may be used to inhibit the action of fatty acid amide hydrolase (FAAH). Inhibition of fatty acid amide hydrolase (FAAH) will slow the normal degradation and inactivation of endogenous cannabinoid ligands by FAAH hydrolysis and allow higher levels of those endogenous cannabinergic ligands to remain present. These higher levels of endocannabinoid ligands provide increased stimulation of the cannabinoid CBl and CB2 receptors and produce physiological effects related to the activation of the cannabinoid receptors. They will also enhance the effects of other exogenous cannabinergic ligands and allow them to produce their effects at lower concentrations as compared to systems in which fatty acid amide hydrolase (FAAH) action is hot inhibited. Thus, a compound that inhibits the inactivation of endogenous cannabinoid ligands by fatty acid amide hydrolase (FAAH) may increase the levels of endocannabinoids and, thus, enhance the activation of cannabinoid receptors. Thus, the compound may not directly modulate the cannabinoid receptors but has the effect of indirectly stimulating the cannabinoid receptors by increasing the levels of endocannabinoid ligands. It may also enhance the effects and duration of action of other exogenous cannabinergic ligands that are administered in order to elicit a cannabinergic response.
    [FR] L'invention concerne des composés de formule R-X-Y qui peuvent être utilisés pour inhiber l'action d'une amide d'acide gras hydrolase (FAAH). L'inhibition d'une amide d'acide gras hydrolase (FAAH) ralentira les dégradation et inactivation normales de ligands cannabinoïdes endogènes par hydrolyse par une FAAH et permettra de conserver des taux supérieurs de ces ligands cannabinergiques endogènes. Lesdits taux supérieurs de ligands endocannabinoïdes assurent une plus grande stimulation des récepteurs CB1 et CB2 cannabinoïdes, et produisent des effets physiologiques se rapportant à l'activation des récepteurs cannabinoïdes. Lesdits taux supérieurs de ligands endocannabinoïdes augmentent également les effets d'autres ligands cannabinergiques exogènes et leur permettent de prendre effets à des concentrations inférieures par rapport aux systèmes dans lesquels l'action d'une amide d'acide gras hydrolase (FAAH) n'est pas inhibée. Ainsi, un composé inhibant l'inactivation de ligands cannabinoïdes endogènes par une amide d'acide gras hydrolase (FAAH) peut augmenter les taux d'endocannabinoïdes et augmenter ainsi l'activation des récepteurs cannabinoïdes. Le composé peut ne pas directement moduler les récepteurs cannabinoïdes mais a l'effet de stimuler indirectement les récepteurs cannabinoïdes par augmentation des taux de ligands endocannabinoïdes. Ledit composé peut également augmenter les effets et la durée d'action d'autres ligands cannabinergiques exogènes administrés de façon à provoquer une réponse cannabinergique.
查看更多

同类化合物

(1Z)-1-(3-乙基-5-羟基-2(3H)-苯并噻唑基)-2-丙酮 齐拉西酮砜 齐帕西酮-d8 阳离子蓝NBLH 阳离子荧光黄4GL 锂2-(4-氨基苯基)-5-甲基-1,3-苯并噻唑-7-磺酸酯 铜酸盐(4-),[2-[2-[[2-[3-[[4-氯-6-[乙基[4-[[2-(硫代氧代)乙基]磺酰]苯基]氨基]-1,3,5-三嗪-2-基]氨基]-2-(羟基-kO)-5-硫代苯基]二氮烯基-kN2]苯基甲基]二氮烯基-kN1]-4-硫代苯酸根(6-)-kO]-,(1:4)氢,(SP-4-3)- 铜羟基氟化物 钾2-(4-氨基苯基)-5-甲基-1,3-苯并噻唑-7-磺酸酯 钠3-(2-{(Z)-[3-(3-磺酸丙基)-1,3-苯并噻唑-2(3H)-亚基]甲基}[1]苯并噻吩并[2,3-d][1,3]噻唑-3-鎓-3-基)-1-丙烷磺酸酯 邻氯苯骈噻唑酮 西贝奈迪 螺[3H-1,3-苯并噻唑-2,1'-环戊烷] 螺[3H-1,3-苯并噻唑-2,1'-环己烷] 葡萄属英A 草酸;N-[1-[4-(2-苯基乙基)哌嗪-1-基]丙-2-基]-2-丙-2-基氧基-1,3-苯并噻唑-6-胺 苯酰胺,N-2-苯并噻唑基-4-(苯基甲氧基)- 苯酚,3-[[2-(三苯代甲基)-2H-四唑-5-基]甲基]- 苯胺,N-(3-苯基-2(3H)-苯并噻唑亚基)- 苯碳杂氧杂脒,N-1,2-苯并异噻唑-3-基- 苯甲酸,4-(6-辛基-2-苯并噻唑基)- 苯甲基2-甲基哌啶-1,2-二羧酸酯 苯并噻唑正离子,2-[3-(1,3-二氢-1,3,3-三甲基-2H-吲哚-2-亚基)-1-丙烯-1-基]-3-乙基-,碘化(1:1) 苯并噻唑正离子,2-[2-[4-(二甲氨基)苯基]乙烯基]-3-乙基-6-甲基-,碘化 苯并噻唑正离子,2-[(2-乙氧基-2-羰基乙基)硫代]-3-甲基-,溴化 苯并噻唑啉 苯并噻唑三氯金(III) 苯并噻唑-d4 苯并噻唑-7-乙酸 苯并噻唑-6-腈 苯并噻唑-5-羧酸 苯并噻唑-5-硼酸频哪醇酯 苯并噻唑-4-醛 苯并噻唑-4-乙酸 苯并噻唑-2-磺酸钠 苯并噻唑-2-磺酸 苯并噻唑-2-磺酰氟 苯并噻唑-2-甲醛 苯并噻唑-2-甲酸 苯并噻唑-2-甲基甲胺 苯并噻唑-2-基磺酰氯 苯并噻唑-2-基甲基-乙基-胺 苯并噻唑-2-基叠氮化物 苯并噻唑-2-基-邻甲苯-胺 苯并噻唑-2-基-己基-胺 苯并噻唑-2-基-(4-氯-苯基)-胺 苯并噻唑-2-基-(4-氟-苯基)-胺 苯并噻唑-2-基-(4-乙氧基-苯基)-胺 苯并噻唑-2-基-(2-甲氧基-苯基)-胺 苯并噻唑-2-基-(2,6-二甲基-苯基)-胺